American Trust lowered its holdings in shares of Humana Inc. (NYSE:HUM – Get Rating) by 6.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 473 shares of the insurance provider’s stock after selling 32 shares during the quarter. American Trust’s holdings in Humana were worth $206,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of HUM. Tcwp LLC purchased a new position in Humana during the first quarter worth approximately $25,000. Riverview Trust Co purchased a new position in Humana during the first quarter worth approximately $32,000. Bank of New Hampshire purchased a new position in Humana during the first quarter worth approximately $36,000. CNB Bank purchased a new position in shares of Humana in the first quarter valued at approximately $44,000. Finally, DeDora Capital Inc. purchased a new position in shares of Humana in the first quarter valued at approximately $48,000. Hedge funds and other institutional investors own 93.50% of the company’s stock.
Humana Price Performance
HUM stock opened at $501.07 on Tuesday. The business has a fifty day moving average of $486.23 and a two-hundred day moving average of $459.58. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.73. The stock has a market cap of $63.41 billion, a price-to-earnings ratio of 20.45, a price-to-earnings-growth ratio of 1.49 and a beta of 0.77. Humana Inc. has a 52-week low of $351.20 and a 52-week high of $504.99.
Humana Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Stockholders of record on Friday, September 30th will be paid a $0.7875 dividend. The ex-dividend date is Thursday, September 29th. This represents a $3.15 dividend on an annualized basis and a dividend yield of 0.63%. Humana’s payout ratio is presently 12.86%.
Analysts Set New Price Targets
Several research firms have recently weighed in on HUM. Loop Capital began coverage on Humana in a research report on Thursday, June 16th. They issued a “buy” rating and a $510.00 target price on the stock. Morgan Stanley raised their target price on Humana from $453.00 to $494.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 2nd. StockNews.com downgraded Humana from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 29th. Sanford C. Bernstein began coverage on Humana in a research report on Thursday, May 26th. They issued a “market perform” rating and a $506.00 target price on the stock. Finally, Oppenheimer raised their target price on Humana from $520.00 to $550.00 and gave the company an “outperform” rating in a research report on Friday. Five analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Humana currently has an average rating of “Moderate Buy” and a consensus price target of $515.17.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Get a free copy of the StockNews.com research report on Humana (HUM)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.